Interestingly, studies of AMD patients carrying the HTRA1 risk allele (rs10490924) reported decreased systemic levels of 2-phenylacetamide compared to non-carriers, although the functional implications remain unclear [51]. This evidence concerns the gene HTRA1 and age-related macular degeneration.